Premium
Cross‐Reactivity in HIV‐infected Patients Switched from Trimethoprim‐Sulfamethoxazole to Dapsone
Author(s) -
Holtzer Christopher D.,
Flaherty John F.,
Coleman Rebecca L.
Publication year - 1998
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1998.tb03904.x
Subject(s) - dapsone , trimethoprim , pneumocystis carinii , medicine , sulfamethoxazole , retrospective cohort study , pneumonia , human immunodeficiency virus (hiv) , cohort , reactivity (psychology) , immunology , surgery , antibiotics , microbiology and biotechnology , pathology , pneumocystis jirovecii , alternative medicine , biology
Study Objective . To evaluate the cross‐reactivity of dapsone after a documented hypersensitivity reaction to trimethoprim‐sulfamethoxazole (TMP‐SMX) during prophylaxis for Pneumocystis carinii pneumonia. Design . Retrospective, chart review, cohort study. Setting . Two university‐affiliated teaching hospitals. Patients . Sixty patients infected with the human immunodeficiency virus. Measurements and Main Results . Thirteen patients (21.7%) had cross‐reactivity to dapsone after the reaction to TMP‐SMX. No significant risk factors for this response were identified. Most reactions were of mild or moderate severity and rated as possibly or probably caused by one of the agents. Of the 13 patients, 4 (30.8%) continued therapy. Conclusions . Although cross‐reactivity can occur, dapsone may be considered in patients with mild hypersensitivity reactions to TMP‐SMX.